Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Equity Income: 2021-2023

Historic Equity Income for ImmunityBio (IBRX) over the last 3 years, with Dec 2023 value amounting to -$7.5 million.

  • ImmunityBio's Equity Income rose 71.84% to -$1.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$11.1 million, marking a year-over-year decrease of 18.67%. This contributed to the annual value of -$7.5 million for FY2023, which is 37.65% up from last year.
  • As of FY2023, ImmunityBio's Equity Income stood at -$7.5 million, which was up 37.65% from -$12.1 million recorded in FY2022.
  • Over the past 5 years, ImmunityBio's Equity Income peaked at -$803,000 during FY2021, and registered a low of -$12.1 million during FY2022.
  • Its 3-year average for Equity Income is -$6.8 million, with a median of -$7.5 million in 2023.
  • In the last 5 years, ImmunityBio's Equity Income tumbled by 1,407.72% in 2022 and then surged by 37.65% in 2023.
  • Yearly analysis of 3 years shows ImmunityBio's Equity Income stood at -$803,000 in 2021, then plummeted by 1,407.72% to -$12.1 million in 2022, then soared by 37.65% to -$7.5 million in 2023.